$11.41
0.524.78%
Last update: Nov 11, 4:16 PM
Sagimet Biosciences Inc
SGMTNASDAQ
Sagimet Biosciences rose 34.2% from $8.50 to a 1-year high of $11.41, ahead of the S&P 500's +9.8%. Its worst day was Sep 24 (−12.6%), and its low came Mar 30 at $4.55.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.40 beat the $-0.40 estimate on $0.00 revenue.
−12.2% · S&P 500 −1.7%
EPS of $-0.29 beat the $-0.41 estimate on $0.00 revenue (est. $1.3M).
Story events cover the past 12 months · Times ET
+3.8% · S&P 500 −0.1%
Sagimet Biosciences closed at its lowest level of the year, 46.5% below where the year started.
−7.0% · S&P 500 −0.3%
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.
+38.6%, the year's best day, on 49M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $-0.33 beat the $-0.36 estimate on $0.00 revenue.
−0.5% · S&P 500 −0.2%
EPS of $-0.26 beat the $-0.27 estimate on $0.00 revenue.
−0.5% · S&P 500 −0.3%
Where it ended: a 1-year high close of $11.41 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.26).
Nothing in the past 12 months.
All SGMT dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SGMT and SPY from Benzinga historical bars. Not investment advice.
